Grace Therapeutics, Inc. (GRCE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$17.0M
Cash & Equivalents
$8.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$40M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05995405 | Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH | PHASE3 | Active Not Recruiting | 100 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-18 | 8-K | Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) - EXHIBIT 99.1 | EDGAR |